Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1889Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 680Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 567Stomach Neoplasms 523Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 404Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × HR+/HER2- Breast Cancer × Clear all
NCT07130643 2025-08-19

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Hubei Cancer Hospital

Phase 2 Active not recruiting
40 enrolled
Breast

HR+/HER2- Breast Cancer

NCT05633914 2023-02-21

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Hunan Cancer Hospital

Phase 2 Unknown
90 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡